Related Experiment Videos
Pivmecillinam treatment of chronic urinary tract infection
Abstract:
Twenty-eight patients with chronic urinary tract infections were treated with 400 mg pivmecillinam orally three times daily for 10 to 15 days. The diagnosis was confirmed by a history of cystitis or cystopyelitis four to six times annually, microscopy of urine sediment, and growth of pathogens in urine specimens obtained by suprapubic bladder puncture. Three days, three and six weeks after completion of therapy the success rates were 24/28, 20/28 and 19/28 respectively. Pivmecillinam was well tolerated. Two patients developed nausea and vomiting. Other side-effects were not observed. Pivmecillinam is a useful drug in the treatment of chronic urinary tract infections.
Insights
Pivmecillinam effectively treats chronic urinary tract infections (UTIs) in patients. This antibiotic demonstrated high success rates with minimal side effects, making it a valuable option for recurrent UTIs.
Area of Science:
- Urology
- Infectious Diseases
- Pharmacology
Background:
- Chronic urinary tract infections (UTIs) pose a significant health challenge.
- Recurrent UTIs require effective and well-tolerated treatment options.
Purpose of the Study:
- To evaluate the efficacy and safety of pivmecillinam for chronic UTIs.
- To assess treatment success rates at various time points post-therapy.
Main Methods:
- Twenty-eight patients with chronic UTIs received oral pivmecillinam (400 mg TID for 10-15 days).
- Diagnosis confirmed via medical history, urine microscopy, and suprapubic bladder puncture culture.
- Success rates assessed 3 days, 3 weeks, and 6 weeks post-treatment.
Main Results:
- Initial success rate was 24/28 patients.
- Rates at 3 weeks and 6 weeks were 20/28 and 19/28, respectively.
- Pivmecillinam was well tolerated; only two patients reported nausea/vomiting.
Conclusions:
- Pivmecillinam is a useful and safe antibiotic for managing chronic UTIs.
- The drug shows sustained efficacy in clearing infections over time.
- It offers a favorable side-effect profile for patients with recurrent infections.